Septerna Inc. (SEPN)
NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
SEPN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.68B
- EPS (TTM)
- -$0.54
- Dividend yield
- None
- 52-week range
- 17.55 – 51.10
- Day range
- 35.21 – 37.14
- Volume / Avg
- 1.03M / 392.67K
- Beta
- —
- Shares outstanding
- 46.68M
- Next earnings
- Nov 9, 2026
52-week range
SEPN stock today
Septerna (SEPN) closed at $36.00 on Oct 7, up 0.93% (+$0.33), versus the S&P 500's 0.22% decline. Volume was 2.6x the average at 1.03M shares, a sign of unusually heavy trading. At this level, SEPN sits in the middle of its 52-week range of $17.55 to $51.10: 29.5% below the high, set on Aug 12, 2026 and 105.1% above the low.
SEPN is up 29.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 71.3%. Septerna has posted a net loss over the last twelve months (EPS of -$0.54), so its P/E ratio is not meaningful. Septerna's next earnings report is expected on Nov 9, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Septerna
Company profileSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jeffrey T. Finer M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 123
- IPO year
- 2024
- Website
- septerna.com
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$54.22+50.61%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 9, 2026
Septerna peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BRVEBraveheart Bio Inc. | 18.58 | -6.11% | $1.67B | vs SEPN |
| ANIPANI Pharmaceuticals Inc. | 71.93 | +0.57% | $1.65B | vs SEPN |
| NUVBNuvation Bio Inc. Class A | 4.86 | -0.41% | $1.71B | vs SEPN |
| CMPSCOMPASS Pathways Plc American Depository Shares | 11.69 | +1.12% | $1.62B | vs SEPN |
| QUREuniQure N.V. | 23.14 | +0.35% | $1.61B | vs SEPN |
| GENBGenerate Biomedicines Inc. | 13.57 | -1.67% | $1.74B | vs SEPN |
| OCULOcular Therapeutix Inc. | 7.23 | -1.50% | $1.59B | vs SEPN |
| ETONEton Pharmaceuticals Inc. | 54.88 | +0.20% | $1.57B | vs SEPN |
Indexes, lists and sector
Septerna stock FAQ
What is Septerna's stock price today?
SEPN last traded at $36.00 as of Oct 7, 4:00 PM EDT, up 0.93% on the day. Prices are delayed at least 15 minutes.
When is Septerna's next earnings date?
Septerna is expected to report earnings on Monday, November 9, 2026.
Who is Septerna's CEO?
Dr. Jeffrey T. Finer M.D., Ph.D. is the chief executive officer of Septerna Inc., which has about 123 employees.
What is the SEPN 52-week high?
The 52-week high for SEPN is $51.10 and the 52-week low is $17.55. The stock is currently 29.5% below its high.